Development of nitrate tolerance is a major drawback to nitrate therapy. Prostacyclin (PGI2) is a powerful vasodilator produced from prostaglandin (PGH2) by prostacyclin synthase (PGIS) in endothelial cells. This study aimed to determine the role of PGIS S-nitrosylation in nitrate tolerance induced by nitroglycerin (GTN). In endothelial cells, GTN increased PGIS S-nitrosylation and disturbed PGH2 metabolism, which were normalized by mutants of PGIS cysteine 231/441 to alanine (C231/441A). Clearance of nitric oxide by carboxy-PTIO or inhibition of S-nitrosylation by N-acetyl-cysteine decreased GTNinduced PGIS S-nitrosylation. Enforced expression of mutated PGIS with C231/441A markedly abolished GTN-induced PGIS S-nitrosylation and nitrate cross-tolerance in Apoe -/-mice. Inhibition of cyclooxygenase 1 by aspirin, supplementation of PGI2 by beraprost, and inhibition of PGIS S-nitrosylation by N-acetyl-cysteine improved GTN-induced nitrate crosstolerance in rats. In patients, increased PGIS S-nitrosylation was associated with nitrate tolerance. In conclusion, GTN induces nitrate cross-tolerance through PGIS S-nitrosylation at cysteine 231/441.
1
However, continuous exposure to GTN or other nitrate esters can lead to nitrate tolerance, causing the loss of vascular responsiveness to nitrates. 2 It is widely used because of its excellent therapeutic profile, although it induces nitrate tolerance. 3 In vasculature, prostacyclin (PGI2) is produced by cyclooxygenases 1 (COX1), which produces prostaglandin (PGH2) from arachidonic acid. 4, 5 PGH2 is transformed enzymatically into PGI2 by PGI2 synthase (PGIS) or into thromboxane A2 (TXA2) by TXA2 synthase. The capacity of blood vessels to generate PGI2 is essential to the integrity of the endothelium to relax VSMC. 6 However, both TXA2 and PGH2 stimulate VSMC contractions via activation of TXA2 receptors (TPr). Functional deficiency of PGIS has been demonstrated to contribute to GTN-induced inflammatory response and nitrovasodilator tolerance. 7 It has been reported that GTN therapy may cause nitrate tolerance through DNA damage, induction of microRNA-199, and endothelial dysfunction. [8] [9] [10] S-nitrosylation is a ubiquitous redox-related modification of cysteine thiol by NO, which transduces NO bioactivity. 11, 12 Accumulating evidence suggests that S-nitrosylation, such as S-nitrosothiols, plays key roles in human health and diseases. 13, 14 Further, GTN therapy may produce Snitrosylation of proteins and induce endothelial dysfunctions. [15] [16] [17] [18] Whether PGIS is S-nitrosylated by NO and its role in nitrate tolerance remain unknown.
In this study, we supposed that PGIS is S-nitrosylated by NO, which contributes to nitrate tolerance. We demonstrated that NO donors induced S-nitrosylation of PGIS and disrupted the balance between PGI2 and TXA2 production in endothelial cells. Overexpression of PGIS protein resistant to S-nitrosylation restored the action of GTN. Further, PGI2 supplementation or COX1 inhibition rescued GTN-induced nitrate tolerance in vivo. This evidence suggests that NO-mediated S-nitrosylation of PGIS serves as a key mechanism for nitrate cross-tolerance.
RESULTS

GTN induces PGIS S-nitrosylation and reduces PGIS activity in rats
To first determine whether PGIS was modified by Snitrosylation, PGIS S-nitrosylation was measured in the in vivo model of nitrate tolerance in rats infused with GTN for 3 days (Supplemental Figure S1A ) as described previously. 17 As shown in Figure 1a , the levels of PGIS S-nitrosylation were remarkably increased in carotid arteries in rats infused with GTN, compared to vehicle-treated rats. GTN-induced PGIS S-nitrosylation was further confirmed by Western blot analysis in aortic artery from GTN-infused rats (Figure 1b ). These data demonstrate that PGIS protein is able to be S-nitrosylated by GTN in vivo.
GTN induces nitrate cross-tolerance, which is endotheliumdependent
To identify the role of PGIS in nitrate tolerance, responses of descending aortic arteries to NO were measured in GTN-infused rats. As shown in Figure S1b , compared to vehicle-treated rats the concentration-dependent responses of aortic rings to GTN were dramatically inhibited. Further, responses of aortic rings to other NO donors, such as sodium nitroprusside (SNP) and S-Nitroso-Nacetylpenicillamines (SNAP), were also suppressed by GTN infusion in rats ( Figure S1c,d) , consistent with other reports. 7, 17 We next examined the roles of endothelium in GTN-induced nitrate tolerance because PGIS is dominantly expressed in endothelial cells. 19 As depicted in Figure S1e -g, responses of aortic rings to GTN, SNP, and SNAP were reversed in aortic rings if the endothelium was removed. Moreover, GTN infusion decreased PGIS activity in rats (Figure 1c) , consistent with other reports. 7 Taking these results together, it shows that GTNinduced nitrate cross-tolerance is limited to endothelium, which is related to PGIS dysfunction.
GTN-induced nitrate tolerance and PGIS S-nitrosylation are abolished by N-acetyl-cysteine in rats
To determine whether PGIS S-nitrosylation contributes to nitrate tolerance, we treated GTN-infused rats with N-acetyl-cysteine (NAC), which serves as a precursor of glutathione synthesis to prevent S-nitrosylation. 20 As shown in Figure 1a -d, administration of NAC completely bypassed PGIS S-nitrosylation in carotid and aortic arteries, reversed PGIS activity, and improved the concentration-dependent responses of aortic rings to GTN. These results not only indicate that GTN-induced nitrate tolerance is dependent on S-nitrosylation, but also reveal the reduction of PGIS activity is possibly due to S-nitrosylation in vivo.
NO donors S-nitrosylate recombinant PGIS protein directly in vitro
NO is a highly reactive gas molecule that may cause functional activation or inhibition of target proteins through posttranslational modifications. 21 We next determined whether GTNinduced S-nitrosylation of PGIS protein in vivo was due to a direct effect of NO. To this point, purified recombinant PGIS protein was incubated with structurally unrelated NO donors including GTN, S-Nitrosoglutathione, SNAP, SNP, and Spermine NONOate. As indicated in Figure 2a ,b, in vitro exposure of recombinant PGIS protein to NO donors increased PGIS Snitrosylation and caused an inhibition of PGIS activity, supporting the notion that GTN-induced PGIS S-nitrosylation is due to a direct modification of PGIS protein by NO.
GTN induces PGIS S-nitrosylation and reduced PGIS activity in human umbilical vein endothelial cells (HUVECs) Knowing that GTN S-nitrosylates recombinant PGIS protein and inhibits PGIS activity in vitro, we next tested the effects of GTN on PGIS S-nitrosylation in cultured HUVECs. As expected, GTN concentration-dependently increased PGIS Snitrosylation ( Figure S2a ) and reduced PGIS activity ( Figure  S2b ) after 8-hour exposure. These data hint that GTN-induced nitrate tolerance might be related to PGIS S-nitrosylation in endothelial cells.
GTN reduces PGIS activity via NO-mediated S-nitrosylation in HUVECs
We next investigated whether GTN reduced PGIS activity via NOmediated S-nitrosylation in HUVECs. NAC and carboxy-PTIO, as an NO scavenger that reacts stoichiometrically with NO, 22 were used to block NO-mediated S-nitrosylation. In Figure 2c ,d, although GTN induced PGIS S-nitrosylation and reduced PGIS activity in HUVECs, both PTIO and NAC abolished PGIS S-nitrosylation and reversed PGIS activity in GTN-treated cells. These data demonstrate that GTN inhibits PGIS activity through NO-mediated Snitrosylation in HUVECs, supporting the concept that Snitrosylation of PGIS contributes to GTN-induced nitrate tolerance.
GTN induces PGIS protein S-nitrosylation at Cys231 or Cys441 in vitro
Since S-nitrosylation is a modification of cysteine thiol by NO, 23 we proposed a mechanism by which NO might directly modify PGIS protein at cysteine residues. To test this notion, we performed analyses of an amino acid sequence in PGIS protein. As shown in Figure S3 , PGIS proteins are highly conserved among human, hamster, bovine, rat, and mouse. In human PGIS protein, cysteine residues at positions of 231 and 441 amino acids (Cys231 and Cys441) are the potential sites that are able to be S-nitrosylated by NO.
Next we compared the in vitro S-nitrosylation of full-length PGIS peptide to PGIS protein with a replacement of either Cys231 or Cys441 or both by alanine. As depicted in Figure 3a , GTNinduced PGIS protein was partially inhibited by replacement of either Cys231 or Cys441 to alanine, and completely abolished by mutations of Cys231 plus Cys441 to alanine. Accordingly, PGIS activity was not suppressed by GTN if Cys231 and Cys441 in PGIS protein were replaced with alanine ( Figure 3b ). These in vitro results demonstrate that GTN induces S-nitrosylation of PGIS protein at Cys231 and Cys441 residues.
Mutants of PGIS at Cys231 and Cys441 to alanine rescue PGIS activity in GTN-treated HUVECs
The S-nitrosylations at Cys231 and Cys441 in PGIS protein by GTN were further confirmed in HUVECs. We generated adenovirus harboring cDNA of wildtype PGIS (WT-PGIS) or mutated PGIS (MT-PGIS) with replacements of Cys231 plus Cys441 to alanine (C231/441A) and infected adenovirus into HUVECs. As shown in Figure 3c , GTN exposure induced PGIS S-nitrosylation in HUVECs infected with adenovirus expressing WT-PGIS but not in HUVECs expressing MT-PGIS. Conversely, the activity of WT-PGIS was lost more than 60% after GTN exposure in HUVECs, while the activity of MT-PGIS was not reduced by GTN in HUVECs (Figure 3d ). These results further indicate GTN-reduced PGIS activity is through S-nitrosylation at Cys231 and Cys441 in HUVECs.
GTN increases the conversion of PGH2 to TXA2 in HUVECs
Decreased PGIS activity may disrupt the metabolism of arachidonic acid and cause the conversion of PGH2 to TXA2 but not to PGI2. 6 Thus, we examined the effects of PGIS S-nitrosylation by GTN in the conversion of PGH2 to TXA2 in endothelial cells. The levels of both PGI2 and TXA2 in HUVECs were measured. As shown in Figure 4a , GTN concentration-dependently decreased the levels of PGI2 but increased the levels of TXA2. The ratio of TXA2 to PGI2 was gradually enhanced by GTN ( Figure S4A ). Overall, our results reveal that GTN inhibits the conversion of PGH2 to PGI2 and increases the transformation of PGH2 to TXA2 in endothelial cells.
GTN-increased the conversion of PGH2 to TXA2 is through NOmediated PGIS S-nitrosylation in HUVECs
To determine the role of PGIS S-nitrosylation in the conversion of PGH2 to TXA2, we also detected the levels of PGI2 and TXA2 in GTN-treated HUVECs in the presence of PTIO and NAC. In Figure 4b , increased TXA2 productions and reduced PGI2 formations were suppressed by S-nitrosylation or NO clearance in GTN-treated HUVECs, accompanied with the normalization of the ratio of TXA2 to PGI2 ( Figure S4B ), demonstrating that GTN through NO-mediated S-nitrosylation upregulates the conversion of PGH2 to TXA2 in endothelial cells.
The role of PGIS S-nitrosylation in the conversion of PGH2 to TXA2 was further confirmed by measuring the levels of PGI2 and TXA2 in HUVECs infected with adenovirus harboring cDNA of WT-PGIS or MT-PGIS (C231/441A). In Figure 4c and Figure S4C , both TXA2 enhancement and PGI2 reduction were not observed in GTN-treated HUVECs with enforced expression of MT-PGIS, compared to HUVECs with overexpression of WT-PGIS.
Mutations of PGIS at Cys231 and Cys441 abolish PGIS Snitrosylation and reverse PGIS activity in vivo
The role of PGIS S-nitrosylation in the conversion of PGH2 to TXA2 was also examined in vivo. To this end, adenovirus containing cDNA of WT-PGIS or MT-PGIS was introduced into 
Apoe
-/-mice via tail injection for 2 weeks followed by 3-day GTN infusion. As indicated in Figure 5a , GTN significantly induced PGIS S-nitrosylation in aortic artery in mice infected with adenovirus expressing WT-PGIS. However, GTN did not increase PGIS S-nitrosylation in mice infected with adenovirus harboring cDNA of MT-PGIS (C231/441A). Expectedly, GTN reduced PGIS activity ( Figure 5b ) and increased the conversion of PGH2 to TXA2 (Figure 5c ) in mice with overexpressed WT-PGIS, but not in mice expressing S-nitrosylation-resistant PGIS. Collectively, this demonstrates that GTN inhibits PGI2 formation and increases TXA2 production through PGIS Snitrosylation in vivo.
Adenovirus-mediated enforced expression of S-nitrosylationresistant PGIS prevents GTN-induced nitrate cross-tolerance in Apoe -/-mice
To examine the role of PGIS S-nitrosylation in GTN-induced nitrate tolerance in vivo, responses of descending aortic arteries to NO donors were measured in Apoe -/-mice. As shown in Figure 5d -f, GTN-infusion dramatically inhibited the responses of artic rings to GTN, SNP, and SNAP in mice infected with adenovirus expressing WT-PGIS. However, the concentrationdependent responses of aortas to NO donors were not impaired in mice with enforced expression of MT-PGIS (C231/441A), suggesting that GTN induces nitrate cross-tolerance via PGIS Snitrosylation and functional deficiency in vivo.
Inhibition of PGIS by tranylcypromine induces nitrate crossresistance ex vivo
Knowing that GTN induces nitrovasodilator resistance via PGIS deficiency, we thought that the pharmacological inhibition of PGIS by tranylcypromine would have a similar effect as GTN. As illustrated in Figure S5a ,b, incubation of aortic rings isolated from rats with tranylcypromine substantially inhibited GTN/ SNP-induced vasorelaxation. These data suggest that PGIS deficiency is crucial to nitrate cross-resistance.
Vasorelaxation induced by sGC activator YC-1 is compromised by PGIS S-nitrosylation in vivo
Previous reports have identified sGC as a major contributor to nitrate cross-tolerance 17 ; therefore, we determined whether PGIS S-nitrosylation affects the relaxation induced by YC-1 as an activator of sGC. 24 As shown in Figure S6 , GTN infusion suppressed the responses of aortic arteries to YC-1 in rats treated with vehicle, but not in rats infused with NAC. In essence, these data imply that PGIS S-nitrosylation eliminates NO signaling in nitrate cross-tolerance.
Administration of beraprost and aspirin prevent nitrate crosstolerance in rats infused with GTN
Since PGIS S-nitrosylation by NO and subsequent disruption of PGH2 to PGI2 are critical to GTN-induced nitrate tolerance, we reasoned that supplementation of PGI2 by beraprost and inhibition of PGH2 by aspirin might prevent nitrate tolerance in vivo. To this point, rats were pretreated with aspirin and beraprost for 2 weeks in the model of nitrate tolerance in rats. Although aspirin and beraprost had no effects in PGIS S-nitrosylation ( Figure 6a ) and activity (Figure 6b) , administration of aspirin and beraprost normalized the responses of aortic arteries to GTN, SNP, and SNAP in GTN-infused rats (Figure 6c-e) . In sum, these data provide the evidence that normalization of arachidonic acid metabolism by targeting PGIS and COX1 would improve nitrate tolerance.
Increased PGIS S-nitrosylation is associated with nitrate tolerance in patients
To provide translational perspectives of this study, we conducted a pilot experiment by collecting samples of left anterior descending (LAD) artery of coronary arteries and blood from patients with coronary heart disease after sudden death and determined the association between PGIS S-nitrosylation and nitrate tolerance in human subjects. As shown in Figure S7A , immunofluorescence (IFC) analysis indicated that the levels of PGIS S-nitrosylation in LAD artery were higher in patients with nitrate tolerance than patients without nitrate tolerance. Accordingly, Figure 6 Administration of aspirin and beraprost prevent nitrate cross-tolerance in rats infused with GTN. Rats were fed with aspirin (10 mg/kg/day) and beraprost (200 lg/kg/day) for 2 weeks in drinking water. Then rats were infused with GTN (50 mg/kg/day) through Alzet osmotic pumps. (a) PGIS Snitrosylation in descending aorta was determined by immunoprecipitation plus Western blot. (b) PGIS activity was measured by using an EIA kit. PGIS activity was determined by calculating the amount of 6-keto-PGF1a. (c-e) Response of descending aortic arteries from rats to (c) GTN, (d) SNP, and (e) SNAP were determined in an organ chamber; 10-15 rats in each group. *P < 0.05 vs. control. #P < 0.05 vs. GTN alone. NS indicates no significance.
PGIS activity was decreased in LAD artery ( Figure S7b) , as well as increased TXA2 and decreased PGI2 ( Figure S7c ) in blood from patients with nitrate tolerance. Collectively, these data suggest that PGIS S-nitrosylation might be related to nitrate tolerance in human patients. Although the pilot experiment did not establish the cause-effect association between PGIS S-nitrosylation and nitrate tolerance, it still implies the important role of PGIS S-nitrosylation in determining the efficiency of nitrate esters in clinical investigations.
Administration of aspirin enhances the effects of GTN-induced vasodilation of LAD artery in human patients
We finally tested the effects of aspirin in GTN-induced LAD arterial dilation in human patients during coronary artery angiograph or percutaneous transluminal coronary angioplasty. To this end, the LAD arterial diameter was measured before and after GTN treatment (100 lg, injection) in human patients taking aspirin at a conventional dose. As shown in Figure S7d ,e, GTN-induced vasorelaxation of the LAD artery was augmented by aspirin administration (mm), compared to patients without taking aspirin. In addition, aspirin increased TXA2 levels and decreased PGI2 levels in blood ( Figure S7f ). These data demonstrate that aspirin administration at a conventional dose is able to augment the beneficial effects of GTN in human patients, revealing the high clinical relevance of the study.
DISCUSSION
In this study we identified a novel modification of PGIS protein under nitrate tolerance conditions. Mechanically, NO derived from GTN S-nitrosylates PGIS protein at cysteine residues and reduces PGIS activity, resulting in PGI2 deficiency and subsequent TXA2-induced TPr activation ( Figure S8) . In this way, GTN induces vascular nitrate cross-tolerance. Therefore, the current study will open new avenues to investigate the role of Snitrosylation in PGIS functional regulation and also provide some insight into drug design for nitrate tolerance, in that targeting PGIS S-nitrosylation to improve the outcome of long-term usage of nitric esters.
A major discovery of the present study is that PGIS protein is posttranslationally modified by NO via S-nitrosylation. Protein posttranslational modifications, including phosphorylation, ubiquitination, nitration, acetylation, glycation, and oxidation, play a key role in many cellular processes. 25 This study provides evidence to support the proposal that PGIS is S-nitrosylated at Cys231 and Cys441 residues by NO. This evidence can be summarized as follows. First, PGIS S-nitrosylation was detectable in GTN-infused cells in mice and rats by using IFC analysis and Western blot. Second, structurally unrelated NO donors directly induce S-nitrosylation of PGIS recombinant protein. Third, mutations of Cys231 and Cys441, in which NO can act by directly modifying cysteine residues on target protein, abolish GTN-induced PGIS S-nitrosylation. Clinical observations also reveal that PGIS is S-nitrosylated in human patients with nitrate tolerance. Till now, posttranslational modification of PGIS protein has been reported to be nitrated by peroxynitrite only. 7 This study is the first to ascertain that PGIS protein is S-nitrosylated by NO. This discovery not only uncovers a novel mechanism of PGIS posttranslational modification, but also broadens the biological roles of S-nitrosylation in cardiovascular diseases.
Another important finding is that PGIS S-nitrosylation in endothelial cells is crucial for GTN-induced nitrate crosstolerance. This conclusion is also supported by several findings. First, PGIS S-nitrosylation is highly associated with reduced PGIS activity in the model of nitrate tolerance in animals and human subjects. Second, prevention of PGIS S-nitrosylation by NAC or mutation of cysteine to alanine (S-nitrosylation resistant) reverses PGIS activity and the responses of aortic arteries to NO donors both in vitro and in vivo. Third, removal of endothelium rescues the responses of VSMCs to NO donors in vivo, suggesting that substances from endothelial cells contribute to nitrate tolerance. Finally, inhibition of PGIS by S-nitrosylation increases the production of TXA2 but reduces the biosynthesis of PGI2 from PGH2. Thus, our results strongly support that GTN-induced nitrate tolerance depends on PGIS S-nitrosylation in endothelial cells.
As reported previously, 7 PGIS protein is posttranslationally modified via tyrosine nitration, causing inactivation of PGIS activity in nitrate tolerance. In this kind of modification, superoxide may preferentially react with NO to form ONOO -, which strongly influences cellular functions and results in tissue injury and organ dysfunction. 26 For example, tyrosine nitration leads to inactivation of PGIS, superoxide dismutase, cytoskeletal actin, and neuronal tyrosine hydroxylase. 27, 28 Although these studies have established that tyrosine nitration is a biomarker of endothelial dysfunction or cell damage in vascular diseases, they do not prove that tyrosine nitration plays a key role in the pathogenesis of vascular diseases. Further, it has been reported that inhibition of mitochondria-derived superoxide promotes GTN tolerance in human blood vessels, 29, 30 indicating that ONOO --dependent tyrosine nitration of PGIS is not essential to nitrate tolerance. Otherwise, S-nitrosylation plays critical roles in diseases including diabetes, infection, and pulmonary hypertension. How S-nitrosylations at Cys231 and Cys441 cause inhibition of PGIS activity needs further investigation.
Substantial clinical literature have reported that PGI2 produces dilatory effects at 4 ng/kg/min on particular pulmonary or systemic vascular resistance in humans, 31, 32 which have demonstrated the clinical relevance of PGI2. In the present study, we expanded the potential application of PGI2 to improve nitrate cross-tolerance by using beraprost, a stable mimic of PGI2. Further, both aspirin and NAC normalized the metabolism of arachidonic acid and prevented nitrate cross-resistance by inhibiting PGH2 production and by suppressing S-nitrosylation modification, respectively ( Figure S8 ). These pharmaceutical approaches should be clinically effective in patients who take nitrate esters over long periods.
METHODS Materials GTN, SNP, SNAP, Spermine NONOate, and CSNO were purchased from Cayman Chemical (Ann Arbor, MI). N-acetyl-cysteine (NAC), carboxyl-PTIO, aspirin, beraprost, and primary S-nitrosylation antibody (cat. no. N5411) were purchased from Sigma (St. Louis, MO). Primary PGIS antibody (sc-20933) and protein A/G plus-agarose was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Tranylcypromine was purchased from Santa Cruz Biotechnology.
Animals and induction of nitrate tolerance
Sprague-Dawley rats (8 6 2 weeks old, 180 6 20 g body weight) and Apoe -/-mice (8-12 weeks old, 25 6 5 g) were purchased from Hua-FuKang Animal Company (Beijing, China). Mice and rats were continuously infused with GTN (50-100 mg/kg/day, 3 days) by using Alzet osmotic pumps (Durect, Cupertino, CA) as described previously. 33 This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal protocol was reviewed and approved by the Animal Care and Use Committee of Shandong University.
Animal experimental protocols
In the first part of the animal study, rats were treated with NAC (50 mg/kg/day) for 7 days. Then rats were infused with GTN (50 mg/ kg/day) for 3 days through osmatic pumps. In the second part of the animal study, Apoe -/-mice were infected with adenovirus via tail vein injection as described previously. 34 After 2-week adenovirus infection, mice were infused with GTN (100 mg/kg/day) for 3 days through osmatic pumps. In the third part of the animal study, rats were fed aspirin (10 mg/kg/day) and beraprost (0.2 mg/kg/day) for 2 weeks in drinking water. Then, rats were infused with GTN (50 mg/kg/day) through Alzet osmotic pumps.
Cell cultures
HUVECs from ATCC (Rockville, MD; AT-9620) were maintained in Medium 200 supplemented with low serum growth supplements as described previously. 35 Isolation of descending aorta and isometric measurement of tension An organ chamber study was performed as described previously. 36 The con- Generation of DNA construct and adenovirus infection to cells or mice WT-PGIS cDNA were purchased from Origene (Rockville, MD). Cys231 and Cys441 residues were replaced with alanine by using the QuikChange kit (Stratagene, La Jolla, CA), according to the manufacturer's instructions. All mutations were confirmed by DNA sequencing. The adenovirus construction encompassing WT-PGIS or MT-PGIS (C231/441A) was generated using the AdMax (Microbix, Mississagua, Canada) and pSilencer adeno 1.0-CMV (Ambion, Austin, TX) systems according to the manufacturers' recommendations. Viruses were packaged and amplified in HEK293A cells and purified using CsCl 2 banding followed by dialysis against 10 mM Tris-buffered saline with 10% glycerol. Titering was performed on HEK293 cells using the Adeno-X Rapid Titer kit (BD Biosciences ClonTech, Palo Alto, CA) according to the manufacturer's instructions. HUVECs were infected with adenovirus overnight in antibiotics-free medium supplemented with 2% fetal bovine serum (FBS). The cells were then washed and incubated in fresh medium for an additional 12 hours before experiments. For infecting mice, adenovirus containing WT-PGIS or MT-PGIS cDNA was injected via tail vein under pressure in 1 ml of phosphate-buffered saline (PBS) with 7.6 3 10 7 IFUs of loaded virus. The concentration of DNA was 10 mg/kg.
Assay of PGIS activity, PGI2, PGH2, and TXA2
The methods used for assaying PGIS activity, PGI2, PGH2, and TXA2 were described previously. 10 Immunoprecipitation and Western blot analysis S-nitrosylated PGIS in cell extracts or tissue homogenates was identified by immunoprecipitation and Western blotting as described previously. 37 
IFC analysis
As described previously, 38 sections were deparaffinized, rehydrated, and blocked with 5% normal serum. Double staining for S-nitrosylation and PGIS was performed by using a kit from Vector Laboratories (Burlingame, CA) according to the protocol provided by the company, and was viewed on an SLM 510 laser scanning confocal microscope (Carl Zeiss Meditec, Jena, Germany).
Patients and sample processing
For the first part of human study, the tissues of LAD arteries were obtained from human patients with or without taking nitrates after sudden death (demographic data for these individuals are listed in Table S1 ). For the second part of the human study, we enrolled 24 patients with coronary atherosclerotic heart disease with or without taking aspirin (demographic data for these individuals are listed in Table  S2 ). During coronary artery angiograph or percutaneous transluminal coronary angioplasty, a single dose of GTN (100 lg) was applied to these patients via intravenous injection and the diameters of LAD arteries before and after GTN injection were recorded. The relaxation rate of LAD artery was calculated according to the ratio (3100%) of DDiameter (diameter after GTN / diameter before GTN) to diameter before GTN. The study protocol was approved by the Ethical Committee of Central South University Xiangya Hospital, and informed consent was obtained from the human subjects.
Statistical analysis
All quantitative results are expressed as mean 6 SEM. The normal distribution of data was tested by the Kolmogorov-Smirnov test before statistical comparisons, and the normality/equal variance was tested to determine whether analysis of variance (ANOVA) was appropriate. All data were analyzed with a one-way ANOVA followed by Bonferroni post-hoc analyses, except for those obtained from the time/concentration courses. Statistical analysis was conducted using IBM SPSS statistics 20.0 (IBM, Armonk, NY), and a two-sided P < 0.05 was considered significant.
Additional Supporting Information may be found in the online version of this article.
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